BIAL appoints Pierluigi Antonelli as Non-Executive Board Member

Porto, April 24, 2024 - BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurology, has announced the appointment of Pierluigi Antonelli, Fresenius Management Board member and Chairman & CEO of Fresenius Kabi, as a non-executive member of its Board of Directors.

Antonio Horta-Osorio, Chairman of BIAL, said: "Pierluigi Antonelli has developed an outstanding professional career in the pharmaceutical and healthcare sector. We are very happy to welcome him to BIAL’s Board of Directors and we are sure we will benefit from his vast experience, further enhancing the Board's capabilities and bringing deep market knowledge”.

Pierluigi Antonelli stated, "after many years in leadership positions in some of the largest companies in the industry, it is clear to me the remarkable path that BIAL has achieved in its 100 years of history. This company clearly represents resilience, strategy, and research capabilities. It is with great satisfaction and a sense of challenge that I accepted to join BIAL’s Board, and I am excited to contribute to the company's ongoing scientific advancements and bringing innovative medicines to the market".

Pierluigi Antonelli has been working in the pharmaceutical industry over the last 25 years having experiences in Life Sciences, Biologics and Generic Drugs sectors. In his previous position, he served as CEO of Angelini Pharma and held senior positions at companies such as Novartis Oncology, Sandoz, Merck & Co, and Bristol-Myers Squibb in the United States and Europe

Pierluigi Antonelli holds an MBA from Kellogg School of Management in the United States and a degree in Economics from the Libera Università Internazionale degli Studi Sociali in Italy.

About BIAL: BIAL is a hundred-year-old innovation-driven biopharmaceutical company aiming to improve people’s lives worldwide. Being a fully integrated company strongly committed to therapeutic innovation, BIAL has established an ambitious R&D program, consistently investing more than 20% of its annual revenue in this field. Key focus areas for the company are the neurosciences and rare diseases. In Europe, BIAL has a production site and R&D unit in Portugal (headquarters) and affiliates in several countries - Spain, Germany, United Kingdom, Italy, and Switzerland -. Additionally, BIAL is present in the US and emerging markets such as Mozambique, Angola, Ivory Coast, and Panama. The company’s internationalization strategy also sought the establishment of partnerships and license agreements, thus collaborating with well-established partners to bring its health solutions to everyone in need. BIAL products are present in fifty countries, fulfilling its purpose of making a real difference in the lives of people living with severe diseases across the world. For more information about BIAL, please visit: www.bial.com